The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F.

@article{Woitok2016TheEE,
  title={The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F.},
  author={Mira Woitok and Diana Klose and Judith Niesen and Wolfgang Richter and Muhammad Suhail Abbas and Christoph W. Stein and Rolf Fendel and Magdalena Stefanie Bialon and Christiane Puettmann and Reinhard Fischer and Stefan Barth and Katharina Kolberg},
  journal={Cancer letters},
  year={2016},
  volume={381 2},
  pages={
          323-30
        }
}
Antibody-drug conjugates (ADCs) combine the potency of cytotoxic drugs with the specificity of monoclonal antibodies (mAbs). Most ADCs are currently generated by the nonspecific conjugation of drug-linker reagents to certain amino acid residues in mAbs, resulting in a heterogeneous product. To overcome this limitation and prepare ADCs with a defined stoichiometry, we use SNAP-tag technology as an alternative conjugation strategy. This allows the site-specific conjugation of O(6)-benzylguanine… CONTINUE READING
BETA
1
Twitter Mention

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 43 REFERENCES

O’Bryant, Antibody-drug conjugates: a clinical pharmacy perspective on an emerging cancer

T. V. Jerjian, A. E. Glode, C.L.L.A. Thompson
  • therapy, Pharmacotherapy
  • 2016
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2004
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Antibody-drug conjugates for cancer therapy.

VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL